GlassScriptPhysician profile
Arif Goreja
NPI 1447215611
$1,692.18
in general payments reported to CMS, 2019-2025
25 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $35.68 · 2021: $209 · 2022: $52.29 · 2023: $252 · 2024: $74.26 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896 · Education: $55.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.62 |
| Education | $55.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $217.55 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Enterprises LLC | $153.98 | 2019 | |
| Medtronic, INC. | $130.02 | 2021-2025 | Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $129.96 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $118.91 | 2019-2025 | |
| Scpharmaceuticals INC. | $115.51 | 2024-2025 | |
| Vifor Pharma, INC. | $102.92 | 2020-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $87.11 | 2023-2025 | |
| Glaxosmithkline, LLC. | $86.46 | 2023-2025 | Benlysta, Shingrix, Jesduvroq |
| Fresenius USA Marketing, INC. | $81.20 | 2019-2024 | Velphoro, Korsuva |
| Genentech USA, INC. | $55.76 | 2025 | Gazyva, Xolair |
| Amgen INC. | $52.95 | 2025 | Tavneos |
| Opko Pharmaceuticals, LLC | $49.06 | 2019 | |
| Calliditas Therapeutics US INC. | $48.26 | 2023 | Tarpeyo |
| Travere Therapeutics, INC. | $43.14 | 2024-2025 | Thiola |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $31.40 | 2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $29.96 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $29.31 | 2025 | Empaveli |
| Ani Pharmaceuticals, INC. | $22.92 | 2025 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $21.56 | 2022 | |
| Ardelyx, INC. | $19.65 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.10 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.83 | 2021 | |
| Lilly USA, LLC | $16.66 | 2025 | Jardiance |
| Tris Pharma INC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arif Goreja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.